非老年癌症患者的衰弱评估经常被忽视，这可能是由于缺乏有效的衰弱筛查工具。本研究旨在评估两种现代衰弱筛查工具的性能，即佛兰德版本的分诊风险筛查工具 (fTRST) 和修改后的 5 项衰弱指数 (mFI-5)，与金标准综合老年评估 (GA) 进行比较）在非老年头颈癌 (HNC) 患者中。我们前瞻性地纳入了 2020 年 1 月至 2022 年 12 月期间在台湾三所学术医院接受根治性同步放化疗 (CCRT) 的 354 名年龄 < 65 岁新诊断 HNC 的连续患者。使用 GA、fTRST 和 mFI-5 对所有患者进行衰弱评估，以评估衰弱与治疗结果之间的关系。根据 GA、mFI-5 和 mFI-5，衰弱发生率分别为 27.1%、37.0% 和 42.4%。分别为fTRST。与 GA 相比，mFI-5 和 fTRST 在识别体弱患者方面表现出良好的预测价值。根据 GA、mFI-5 和 fTRST 定义的虚弱患者表现出较高的治疗相关并发症风险、不完整治疗和较差的基线生活质量 (QoL)。然而，只有 GA 对总体生存具有显着的预后价值。使用 fTRST 和 mFI-5 进行衰弱评估对于预测非老年 HNC 患者的治疗相关不良事件、治疗耐受性和生活质量很有价值。将衰弱评估纳入非老年癌症患者的管理中可以帮助识别高风险个体。然而，这些工具的性能各不相同，凸显了进一步验证和完善的必要性。版权所有 © 2023。由 Elsevier Ltd 出版。

Frailty assessment is often overlooked in non-elderly patients with cancer, possibly due to the lack of an effective frailty screening tool. This study aimed to evaluate the performance of two modern frailty screening tools, the Flemish version of the Triage Risk Screening Tool (fTRST) and the modified 5-Item Frailty Index (mFI-5), compared to the gold standard comprehensive geriatric assessment (GA) among non-elderly patients with head and neck cancer (HNC).We prospectively included 354 consecutive patients aged < 65 years with newly diagnosed HNC scheduled for definitive concurrent chemoradiotherapy (CCRT) at three academic hospitals in Taiwan between January 2020 and December 2022. Frailty assessment using the GA, fTRST, and mFI-5 was performed in all patients to evaluate the relationship between frailty and treatment outcomes.The prevalence of frailty was 27.1%, 37.0%, and 42.4% based on GA, mFI-5, and fTRST, respectively. mFI-5 and fTRST demonstrated good predictive value in identifying frail patients compared to the GA. Patients with frailty, as defined by GA, mFI-5, and fTRST, exhibited higher risks of treatment-related complications, incomplete treatment, and poorer baseline quality of life (QoL). However, only GA showed significant prognostic value for overall survival.Frailty assessment using fTRST and mFI-5 is valuable for predicting treatment-related adverse events, treatment tolerance, and QoL in non-elderly patients with HNC. Incorporating frailty assessment into the management of non-elderly cancer patients can aid in the identification of high-risk individuals. However, the performance of these tools varies, highlighting the need for further validation and refinement.Copyright © 2023. Published by Elsevier Ltd.